Figure 1.
Study design. CR, complete response; DLT, dose-limiting toxicity.
Table 1.
Demographics and baseline characteristics of obatoclax-treated patients (N = 18).
Figure 2.
Patient disposition. AE, adverse event; CR, complete response.
Table 2.
Study drug exposure in patients treated with obatoclax (N = 18).
Table 3.
Summary of dose-limiting toxicities and serious adverse events.
Table 4.
Treatment-emergent adverse events occurring in more than one patient.
Table 5.
Improvement in marrow blast count, neutrophil count, and platelet count in patients receiving obatoclax.